Press releases

2016-07-28 - 19:35

BUSINESS UPDATE - SECOND QUARTER 2016

2016-07-07 - 20:30

Disclosure of the total number of voting rights and shares composing the share capital

2016-07-06 - 19:35

GENTICEL APPOINTS EUMEDIX AS STRATEGIC ADVISOR TO SUPPORT COMPANY'S ACCESS TO INNOVATIVE DRUG CANDIDATES

2016-06-23 - 18:45

GENTICEL REPORTS 18 MONTH INTERIM ANALYSIS OF GTL001 PHASE 2 TRIAL IN HPV16/18 INFECTED WOMEN

2016-06-15 - 20:30

GENTICEL TO PRESENT CLINICAL RESULTS OF GTL001 AND PRECLINICAL RESULTS OF GTL002 AT EUROGIN 2016 CONGRESS IN SALZBURG, AUSTRIA

2016-06-13 - 19:35

GENTICEL ANNOUNCES COMPLETION OF TWO MAJOR MILESTONES IN PREPARATION FOR PHASE 3 PROGRAM OF GTL001

2016-06-08 - 19:35

Disclosure of the total number of voting rights and shares composing the share capital

2016-06-01 - 20:00

GENTICEL ANNOUNCES PUBLICATION IN 'CLINICAL CANCER RESEARCH' OF PHASE 1 TRIAL RESULTS SUPPORTING SAFETY, TOLERABILITY AND IMMUNOGENICITY OF GTL001

2016-05-11 - 09:00

Disclosure of the total number of voting rights and shares composing the share capital

2016-04-28 - 19:35

BUSINESS UPDATE - FIRST QUARTER 2016

2016-04-26 - 19:35

PUBLICATION OF THE 2015 ANNUAL FINANCIAL REPORT

2016-04-21 - 20:45

PUBLICATION OF THE FIRST ISSUE OF GENTICEL'S SHAREHOLDER NEWSLETTER

2016-04-20 - 19:30

GENTICEL REPORTS ADDITIONAL RESULTS AT 12 MONTHS FROM PHASE 2 TRIAL OF HPV IMMUNOTHERAPEUTIC CANDIDATE, GTL001

2016-04-06 - 19:00

Disclosure of the total number of voting rights and shares composing the share capital

2016-03-14 - 07:00

GENTICEL ANNOUNCES 2015 ANNUAL RESULTS AND STRATEGIC UPDATE FOR 2016

2016-03-10 - 18:30

GENTICEL UPDATES ITS FINANCIAL CALENDAR FOR 2016 AND ANNOUNCES PARTICIPATION IN KEY CONFERENCES IN H1 2016

2016-01-27 - 18:40

GENTICEL REPORTS INITIAL RESULTS AT 12 MONTHS FROM PHASE 2 TRIAL OF HPV IMMUNOTHERAPEUTIC CANDIDATE, GTL001

2016-01-25 - 18:00

BUSINESS UPDATE - FOURTH QUARTER 2015

2016-01-11 - 08:30

GENTICEL ANNOUNCES ITS FINANCIAL CALENDAR FOR 2016

2016-01-07 - 18:00

SUMMARY OF GENTICEL'S LIQUIDITY CONTRACT WITH ODDO CORPORATE FINANCE

2016-01-07 - 18:00

Disclosure of the total number of voting rights and shares composing the share capital

2016-01-07 - 07:30

GENTICEL TO EVALUATE ROCHE MOLECULAR SYSTEMS' COBAS® HPV TEST IN PREPARATION FOR PHASE 3 PROGRAM OF GTL001

2016-01-05 - 19:00

Genticel appoints Rémi Palmantier, PhD, as Chief Scientific Officer to accelerate its development

2015-12-10 - 18:15

Disclosure of the total number of voting rights and shares composing the share capital

2015-12-02 - 18:00

Benedikt Timmerman resumes CEO position at Genticel

2015-10-29 - 18:00

Genticel Announces First Patient Treated in U.S. Phase 1 Clinical Trial of GTL001, Company's Therapeutic Vaccine Candidate against HPV 16/18 Infections

2015-10-28 - 18:45

Business Update - Third Quarter 2015

2015-09-28 - 19:00

Disclosure of the total number of voting rights and shares composing the share capital

2015-09-21 - 18:40

Genticel presents first half 2015 financial results, operational progress and outlook

2015-09-08 - 08:30

US patent granted for use of Genticel's antigen delivery vectors in combination therapy to treat cancer

2015-09-01 - 19:00

GENTICEL to meet investors

2015-07-28 - 19:00

Business Update - Second Quarter 2015

2015-07-07 - 19:00

Independent Data Safety Monitoring Board Recommends Continuation per Protocol of Genticel's Phase 2 Clinical Trial of GTL001 (ProCervix), Company's First-in-class HPV Therapeutic Vaccine Candidate

2015-07-03 - 19:00

Summary of Genticel's liquidity contract with Oddo Corporate Finance

2015-07-02 - 16:15

Genticel CFO, Martin Koch, Appointed CEO to Replace Benedikt Timmerman during Temporary Medical Leave of Absence

2015-06-16 - 08:00

Genticel Receives FDA Clearance of IND Application for U.S. Phase 1 Clinical Trial of GTL001 (ProCervix), Company's First-in-class HPV Therapeutic Vaccine Candidate

2015-06-01 - 08:00

Genticel Announces Positive Preclinical Proof of Concept Results of GTL002, its New Multivalent HPV Therapeutic Vaccine Candidate Based on Company's Versatile Vaxiclase Platform

2015-05-21 - 19:00

Documents Available for Annual General Meeting of Shareholders

2015-04-28 - 20:00

Business Update - First Quarter 2015

2015-04-23 - 19:00

Genticel to Participate in SmallCap Event on April 27 - 28 in Paris, France

2015-04-20 - 19:40

Genticel to Present Further Promising Pharmacology In-Vivo Results of its Phase 2 Immunotherapeutic Vaccine Candidate, GTL001 (ProCervix), at AACR Annual Meeting 2015

2015-04-09 - 20:20

Genticel strengthens management team and appoints Valerie Leroy as Senior Director, Corporate Communications and Investor Relations

2015-04-01 - 18:00

2014 Reference Document Available with Annual Financial Report

2015-03-24 - 18:50

Eligibility of Genticel shares for PEA-PME

2015-03-06 - 18:00

Implementation of a Programmed Trading Mandate

2015-03-02 - 19:00

2014 Annual Results

2015-02-05 - 16:30

Genticel presents pipeline development in EUROGIN congress held in Seville, Spain - 4 to 7 February 2015

2015-02-02 - 18:30

Genticel licenses Vaxiclase platform to Serum Institute of India for use in pertussis vaccines

2015-01-27 - 19:20

Business Update - Fourth Quarter 2014

2015-01-26 - 20:15

Genticel to continue per protocol its Phase 2 clinical study with ProCervix after 2nd review by the DSMB